

# GLUCAGON AND HIGH DOSE INSULIN FOR TREATMENT OF BETA BLOCKER/ CALCIUM CHANNEL BLOCKER OVERDOSE ADULTS ONLY



<b>TARGET AUDIENCE</b>	For use within NHS Lanarkshire ED / Critical Care only
<b>PATIENT GROUP</b>	Adults only

## Clinical Guidelines Summary

- Collated information required in a high stress situation, for use with adult patients following beta blocker/ calcium channel blocker overdose.
- Administration and monitoring of glucagon and high dose insulin therapy within an observed and monitored ED / Critical Care area.
- Flow chart decision making tool based on Toxbase guidance

# Glucagon Intravenous Infusion (Unlicensed) – Adults only

**\*\*(For use within an observed and monitored ED / Critical Care area only)\*\***

Use as a poisoning antidote: log in to <https://toxbase.org> using your personal Toxbase username and password.

Serious cases of beta blocker overdose should be discussed with the National Poisons Information Service (Tel: **0344 892 0111**).

Glucagon availability: **vials in the ITU treatment room fridge**, ED, and emergency drug cupboard. Liaise with pharmacy as soon as possible, if out of hours contact on call pharmacist through switchboard.

## Beta-blocker overdose (unlicensed) IV injection:

- Give initial IV bolus of 5-10 milligrams (over 1-2 minutes).
- If after initial IV bolus haemodynamic stability is achieved, consider following with IV infusion using an infusion pump.
- Based on actual body weight (ABW) administer at a rate of 50-150 micrograms/kg/hour according to response.
- **Limited evidence for use of doses >10 milligrams/hour.**
- If haemodynamic stability is not achieved after initial IV bolus, an infusion is unlikely to be of benefit.
- **Adult example calculation table for glucagon infusion 50 micrograms/kg/hour in beta-blocker overdose, assuming the reconstituted solution (1 milligram in 1mL) is administered without further dilution.**

Weight (kg)	50 micrograms/kg/hr Rate (mL/hr)	100 micrograms /kg/hr Rate (mL/hr)	150 micrograms /kg/hr Rate (mL/hr)
40	2	4	6
50	2.5	5	7.5
60	3	6	9
70	3.5	7	10.5
80	4	8	12
90	4.5	9	13.5
100	5	10	15
≥110	5.5	11	16.5

**\*\*Allocate 1 person to solely focus on preparation of the infusion as multiple vials are required\*\***

## Preparation:

- Inject 1.1mL water for injections into the contents of the vial containing the glucagon to obtain a reconstituted solution containing glucagon 1milligram in 1mL. TOXBASE advises reconstituted solution can be used undiluted or diluted in 5% glucose.
- Shake the vial gently until the powder is completely dissolved and the solution is clear.
- Withdraw the solution back into the syringe.
- Wean IV infusion slowly and flush with 5% glucose (**unless there are other causes for shock**). Follow local guidelines and guidance of medical staff.
- ***Use a central venous access device where possible to avoid potential venous irritation as the preparation has a low pH. Alternatively administer via a large peripheral vein while monitoring insertion site closely for irritation/extravasation.***


Lead Author	Deborah Smith & Sarah Brady	Date approved	December 2025
Version	1.4b	Review Date	December 2027

Uncontrolled when printed - access the most up to date version on [www.nhsguidelines.scot.nhs.uk](http://www.nhsguidelines.scot.nhs.uk)

# High Dose Insulin Euglycaemic Therapy – Adults only

**\*\* (For use within an observed and monitored ED / Critical Care area only) \*\***

**This is a life threatening emergency, correct hypokalaemia and check blood glucose**



Take 500 units/5mL from a vial of Actrapid (100 units/mL) and dilute with 45mL sodium chloride 0.9% to a final volume of 50 mL (final concentration 10 units/mL). **\*\*Note high strength – label carefully \*\***

**Commence therapy with a bolus of intravenous insulin:** bolus Actrapid at 1.0 unit/kg intravenously over 2-3 minutes (see table overleaf)

**Continue therapy with a continuous intravenous infusion of insulin:** Start at 1.0 unit/kg/hour

**Perform blood glucose (BM) every 10 minutes initially and following insulin infusion rate changes. When on a stable dose check blood glucose (BM) every 30-60 minutes.**

**Measure serum potassium hourly** if  $K^+ < 3.5 \text{ mmol/L}$  replace potassium to normal serum concentration

Titrate the insulin infusion by **1 unit/kg/hour every 15 minutes** to clinical response (aim systolic BP  $> 90 \text{ mmHg}$ ) (See table overleaf)

**Stopping:** Once clinically improved and haemodynamically stable, unless there are other causes for shock, wean vasopressor before discontinuation of insulin infusion under the guidance of medical staff.

- Halve the dose of the insulin infusion and observe for 2 hours. In the absence of a fall in blood pressure, stop the infusion.
- If blood pressure falls restart the infusion and attempt to wean at a later time.
- **High risk of rebound hyperkalaemia once infusion stopped.**
- **Continue to monitor blood glucose (BM) and potassium closely for 24 hours.**

Lead Author	Deborah Smith & Sarah Brady	Date approved	December 2025
Version	1.4b	Review Date	December 2027

## High Dose Insulin Euglycaemic Therapy – Adults only

**\*\* (For use within an observed and monitored ED / Critical Care area only) \*\***

Check K+ prior to starting insulin, if K+ <3.5mmol/L ensure K+ IVI commenced prior to starting/ or when starting high dose insulin

### Actrapid IV infusion 10 units/mL

Patients <u>actual</u> <u>body weight</u> (kg)	<u>Initial bolus</u> <u>dose</u> (1.0 unit/kg)	Initial <u>continuous</u> <u>infusion</u>  (1.0 unit/kg/hour)  mL/hour	Titrate the continuous infusion dose up by 1.0 unit/kg/hour every 15 minutes to clinical response (systolic >90mmHg)			
			(2.0 unit/kg/hr) If no clinical response <b>after 15 minutes</b> of commencing infusion increase to (3.0 unit/kg/hr) and check line	(3.0 unit/kg/hr) If no clinical response <b>after 30 minutes</b> of commencing infusion increase to (4.0 unit/kg/hr) and check line	(4.0 unit/kg/hr) If no clinical response <b>after 45 minutes</b> of commencing infusion increase to (5.0 unit/kg/hr) and check line	(5.0 unit/kg/hr) If no clinical response <b>after 60 minutes</b> of commencing infusion check line and seek further guidance if not already done so
40	40 units (4mL)	4 mL/hour	8 mL/hour	12 mL/hour	16 mL/hour	20 mL/hour
50	50 units (5mL)	5 mL/hour	10 mL/hour	15 mL/hour	20 mL/hour	25 mL/hour
60	60 units (6mL)	6 mL/hour	12 mL/hour	18 mL/hour	24 mL/hour	30 mL/hour
70	70 units (7mL)	7 mL/hour	14 mL/hour	21 mL/hour	28 mL/hour	35 mL/hour
80	80 units (8mL)	8 mL/hour	16 mL/hour	24 mL/hour	32 mL/hour	40 mL/hour
90	90 units (9mL)	9 mL/hour	18 mL/hour	27 mL/hour	36 mL/hour	45 mL/hour
100	100 units (10mL)	10 mL/hour	15 mL/hour	25 mL/hour	35 mL/hour	45 mL/hour
≥110	110 units (11mL)	11 mL/hour	22 mL/hour	33 mL/hour	44 mL/hour	55 mL/hour

**\*\*Note high risk of rebound hyperkalaemia when high dose insulin stopped. Monitor K+ levels closely\*\***

Lead Author	Deborah Smith & Sarah Brady	Date approved	December 2025
Version	1.4b	Review Date	December 2027

Uncontrolled when printed - access the most up to date version on [www.nhsguidelines.scot.nhs.uk](http://www.nhsguidelines.scot.nhs.uk)

## References/Evidence

Adapted from TOXBASE protocol <https://toxbase.org>

Personal communication with TOXBASE professionals <https://toxbase.org>

<b>Lead Author</b>	<b>Deborah Smith &amp; Sarah Brady</b>	<b>Date approved</b>	<b>December 2025</b>
<b>Version</b>	<b>1.4b</b>	<b>Review Date</b>	<b>December 2027</b>

## Appendices

### 1. Governance information for Guidance document

<b>Lead Author(s):</b>	<b>Deborah Smith</b> , Clinical Nurse Educator, Critical Care, University Hospital Hairmyres; <b>Sarah Brady</b> , Senior Pharmacist – Medicines Information/ Surgery & Critical Care, University Hospital Hairmyres
<b>Endorsing Body:</b>	ADTC
<b>Version Number:</b>	1.4b
<b>Approval date</b>	<b>December 2025</b>
<b>Review Date:</b>	December 2027
<b>Responsible Person (if different from lead author)</b>	

CONSULTATION AND DISTRIBUTION RECORD	
<b>Contributing Author / Authors</b>	Deborah Smith, Critical Care Clinical Nurse Educator, University Hospital Hairmyres; Sarah Brady, Senior Pharmacist – Medicines Information/ Surgery & Critical Care, University Hospital Hairmyres
<b>Consultation Process / Stakeholders:</b>	Discussed and altered with feedback from ITU Consultants from UHH/ UHM/ UHW; UHH ITU SCN Dixon; UHH ED Consultants
<b>Distribution</b>	UHH/ UHM/ UHW ITU Anaesthetic Consultants and Anaesthetic Trainees; UHH/ UHM/ UHW Emergency Department Consultants; UHH/ UHM/ UHW ITU Senior Charge Nurse; UHH/ UHM/ UHW ED Senior Charge Nurse; UHH/ UHM/ UHW Clinical Nurse Educators for Critical Care

CHANGE RECORD			
Date	Lead Author	Change	Version
06/06/2025	Deborah Smith & Sarah Brady	<i>Initial development of guidance</i>	1
10/07/2025	Deborah Smith & Sarah Brady	<i>Further alteration to allow for standardisation across NHSL ITU/ ED/ Adult Critical Care</i>	1.3
22/10/2025	Deborah Smith & Sarah Brady	<i>Further alteration to allow for standardisation across NHSL ITU/ ED/ Adult Critical Care</i>	1.4
01/12/2025	Deborah Smith & Sarah Brady	<i>Further alteration to allow for standardisation across NHSL ITU/ ED/ Adult Critical Care</i>	1.4b

<b>Lead Author</b>	Deborah Smith & Sarah Brady	<b>Date approved</b>	December 2025
<b>Version</b>	1.4b	<b>Review Date</b>	December 2027

<b>Lead Author</b>	<b>Deborah Smith &amp; Sarah Brady</b>	<b>Date approved</b>	<b>December 2025</b>
<b>Version</b>	<b>1.4b</b>	<b>Review Date</b>	<b>December 2027</b>

*Uncontrolled when printed - access the most up to date version on [www.nhsguidelines.scot.nhs.uk](http://www.nhsguidelines.scot.nhs.uk)*